Published in Br J Cancer on March 01, 1994
Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J (1996) 1.82
Nitric oxide-induced apoptosis: p53-dependent and p53-independent signalling pathways. Biochem J (1996) 1.50
Decreased DNA repair but normal apoptosis in ultraviolet-irradiated skin of p53-transgenic mice. Am J Pathol (1996) 1.13
Single base discrimination for ribonuclease H-dependent antisense effects within intact human leukaemia cells. Nucleic Acids Res (1995) 1.05
Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Br J Cancer (1996) 1.05
Outgrowth of BT-474 human breast cancer cells in immune-deficient mice: a new in vivo model for hormone-dependent breast cancer. Br J Cancer (1995) 0.96
p53 facilitates pRb cleavage in IL-3-deprived cells: novel pro-apoptotic activity of p53. EMBO J (1998) 0.90
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Induction of apoptosis in fibroblasts by c-myc protein. Cell (1992) 16.95
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (1990) 14.46
p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (1993) 13.46
The p53 proto-oncogene can act as a suppressor of transformation. Cell (1989) 11.67
Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (1990) 11.18
Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (1993) 10.72
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (1991) 9.21
Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J (1990) 6.34
Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci U S A (1992) 5.94
Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci U S A (1989) 5.40
p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol (1990) 5.20
Apoptosis: mechanisms and roles in pathology. Int Rev Exp Pathol (1991) 4.89
Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem (1986) 4.80
Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature (1992) 4.75
Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell (1991) 4.12
Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol (1989) 3.89
Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature (1990) 3.80
Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci U S A (1990) 3.20
Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells. EMBO J (1985) 3.18
Monoclonal antibodies against simian virus 40 nuclear large T tumour antigen: epitope mapping, papova virus cross-reaction and cell surface staining. EMBO J (1984) 2.08
Autocrine secretion of GM-CSF in acute myeloblastic leukemia. Blood (1986) 1.53
Human wild-type p53 adopts a unique conformational and phosphorylation state in vivo during growth arrest of glioblastoma cells. Oncogene (1992) 1.17
A conformation hypothesis for the suppressor and promoter functions of p53 in cell growth control and in cancer. Proc Biol Sci (1991) 1.11
Rescue from programmed cell death in leukemic and normal myeloid cells. Blood (1991) 1.10
Production of leukemic blast growth factor by a human bladder carcinoma cell line. Blood (1985) 0.95
Hematopoietic growth factors and their receptors in acute leukemia. Blood (1993) 0.91
Autocrine growth factors and leukaemic haemopoiesis. Blood Rev (1992) 0.91
Heterogeneous mechanisms of autocrine growth of AML blasts. Br J Haematol (1989) 0.82
Expression of different conformations of p53 in the blast cells of acute myeloblastic leukaemia is related to in vitro growth characteristics. Br J Cancer (1993) 0.81
Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide. Br J Haematol (1997) 1.48
Intensive treatment of renal failure in patients with myeloma. Clin Lab Haematol (1994) 1.43
Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor) Blood (1995) 1.43
Economic evaluation of peripheral blood stem cell transplantation for lymphoma. Lancet (1992) 1.40
Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol (2001) 1.36
Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (1998) 1.30
Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles. Leukemia (2009) 1.29
Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation. Lancet (1993) 1.24
Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. Blood (1999) 1.18
Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant (2010) 1.16
Microsatellite instability occurs in defined subsets of patients with acute myeloblastic leukaemia. Br J Haematol (2001) 1.10
Pregnancy associated aplastic anaemia: a report of five cases and review of current management. Br J Haematol (1989) 1.08
Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant (2008) 1.08
Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol (2003) 1.05
Effective prevention of acute GVHD following allogeneic BMT with low leukaemic relapse using methotrexate and therapeutically monitored levels of cyclosporin A. Bone Marrow Transplant (1992) 1.01
Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia. Leukemia (2009) 1.01
Functional hyposplenism following allogeneic bone marrow transplantation. J Clin Pathol (1995) 0.99
DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412. Leukemia (2006) 0.98
Abnormal fibrinolytic activity in systemic lupus erythematosus and possible mechanisms. Br J Rheumatol (1988) 0.98
The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. Bone Marrow Transplant (2005) 0.98
Bone marrow transplantation: current situation, complications and prevention. J Antimicrob Chemother (1995) 0.97
Fusion of NUP214 to ABL1 on amplified episomes in T-ALL--implications for treatment. Leukemia (2005) 0.97
Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br J Haematol (2004) 0.94
Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation. Bone Marrow Transplant (2011) 0.94
Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia (1995) 0.93
Allogeneic bone marrow transplantation for systemic AL amyloidosis. Br J Haematol (1998) 0.89
Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol (1997) 0.89
Accelerated telomere shortening following allogeneic transplantation is independent of the cell source and occurs within the first year post transplant. Bone Marrow Transplant (2001) 0.89
Clinical impact of MRSA in a stem cell transplant unit: analysis before, during and after an MRSA outbreak. Bone Marrow Transplant (2007) 0.88
Minimal residual disease after bone marrow transplantation for multiple myeloma: evidence for cure in long-term survivors. Bone Marrow Transplant (1993) 0.87
The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry. Leukemia (2010) 0.87
Interleukin-1beta maintains an apoptosis-resistant phenotype in the blast cells of acute myeloid leukaemia via multiple pathways. Leukemia (2004) 0.86
Extramedullary haemopoiesis as a cause of mediastinal lymphadenopathy in chronic myelomonocytic leukaemia. Clin Lab Haematol (1990) 0.86
Visceral varicella zoster infection after bone marrow transplantation without skin involvement and the use of PCR for diagnosis. Bone Marrow Transplant (1995) 0.86
Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion. Cytotherapy (2001) 0.86
A novel BCR-ABL fusion gene (e2/1a) in a patient with Philadelphia-positive chronic myelogenous leukaemia and an aggressive clinical course. Br J Haematol (1998) 0.85
Cobalamin and folate binding proteins in human tumour tissue. J Clin Pathol (1984) 0.85
Thrombocytopathy in preleukaemia: association with a defect of thromboxane A2 activity. Br J Haematol (1979) 0.85
Methylation of the hMLH1 promoter and its association with microsatellite instability in acute myeloid leukemia. Leukemia (2003) 0.84
Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant. Bone Marrow Transplant (2007) 0.84
The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia. Bone Marrow Transplant (2000) 0.84
Allogeneic peripheral blood stem cell transplantation for haematological malignancies--an analysis of kinetics of engraftment and GVHD risk. Bone Marrow Transplant (1997) 0.84
Early allogeneic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG. Leukemia (1999) 0.84
Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients. Br J Haematol (1994) 0.84
Bcl-x(L) is heterogenously expressed by acute myeloblastic leukaemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression. Leukemia (1997) 0.83
An analysis of the effect of chronic GvHD on relapse and survival following allogeneic PBSC transplantation. Cytotherapy (2000) 0.83
Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial. Leukemia (2012) 0.82
Down-regulation of bcl-2 in AML blasts by all-trans retinoic acid and its relationship to CD34 antigen expression. Br J Haematol (1996) 0.82
Heterogeneous mechanisms of autocrine growth of AML blasts. Br J Haematol (1989) 0.82
Evidence for internal autocrine regulation of growth in acute myeloblastic leukemia cells. Exp Hematol (1994) 0.82
Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. Br J Haematol (2000) 0.82
Flow cytometric chemosensitivity analysis of blasts from patients with acute myeloblastic leukemia and myelodysplastic syndromes: the use of 7AAD with antibodies to CD45 or CD34. Cytometry (1999) 0.81
Nosocomial transmission of Saccharomyces cerevisiae in bone marrow transplant patients. J Hosp Infect (2002) 0.81
Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning--evidence for a superior outcome using melphalan combined with total body irradiation. Br J Haematol (2005) 0.81
Expression of different conformations of p53 in the blast cells of acute myeloblastic leukaemia is related to in vitro growth characteristics. Br J Cancer (1993) 0.81
Effect of erythropoietin in patients with myeloma. BMJ (1990) 0.81
DNA repair mechanisms and acute myeloblastic leukemia. Hematol Oncol (2000) 0.80
Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a British National Lymphoma Investigation double-blind, placebo-controlled trial. Br J Haematol (1992) 0.80
Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion/plasmacytoma despite ongoing molecular remission. Bone Marrow Transplant (2003) 0.80
Comparative quantitative expression of bcl-2 by normal and leukaemic myeloid cells. Br J Haematol (1995) 0.79
Macrophage-inflammatory protein-1alpha receptor expression on normal and chronic myeloid leukemia CD34+ cells. J Immunol (1999) 0.79
Absence of retinoblastoma protein expression results in autocrine production of interleukin-6 and promotes the autonomous growth of acute myeloid leukemia blast cells. Leukemia (1994) 0.79
Successful therapy with ribavirin of late onset respiratory syncytial virus pneumonitis complicating allogeneic bone transplantation. Clin Lab Haematol (1992) 0.79
Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a 'graft vs. myelofibrosis' effect. Br J Haematol (2000) 0.79
Engraftment and molecular monitoring of CD34+ peripheral-blood stem-cell transplants for follicular lymphoma: a pilot study. J Clin Oncol (1997) 0.79
Bcl-2 expression in acute myeloblastic leukaemia: relationship with autonomous growth and CD34 antigen expression. Leuk Lymphoma (1997) 0.79
High dose melphalan or intermediate dose melphalan can be well tolerated and result in good response rates in selected elderly patients with myeloma. Leuk Res (2007) 0.78
Detection of clonal immunoglobulin gene rearrangements in the peripheral blood progenitor cells of patients with multiple myeloma: the potential role of purging with CD34 positive selection. Clin Mol Pathol (1996) 0.78
Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: conditioning protocols and donor selection algorithms. Bone Marrow Transplant (2009) 0.78
The effect of deoxycoformycin and deoxyadenosine on deoxyribonucleotide concentrations in leukaemic cells. Br J Haematol (1982) 0.78
Vincristine, adriamycin and high dose steroids in myeloma complicated by renal failure. Br J Cancer (1990) 0.78
Therapeutic selectivity of and predication of response to 2'-deoxycoformycin in acute leukaemia. Lancet (1981) 0.78
Cerebral vasculitis associated with hairy cell leukemia. Cancer (1987) 0.78
Studies on the biochemical sequelae of therapy in Thy-acute lymphoblastic leukaemia with the adenosine deaminase inhibitor 2' deoxycoformycin. Br J Haematol (1981) 0.77
Comparative study of CD34-positive cells and subpopulations in human umbilical cord blood and bone marrow. Bone Marrow Transplant (1993) 0.77
Naso-jejunal feeding in allogeneic bone marrow transplant recipients: results of a pilot study. Bone Marrow Transplant (2001) 0.77
Functional multidrug resistance in acute myeloblastic leukaemia: a standardized flow cytometric assay for intracellular daunorubicin accumulation. Br J Haematol (1998) 0.77
Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis. Bone Marrow Transplant (1998) 0.77
Peripheral blood stem cell transplants. J Clin Pathol (1998) 0.77
Engraftment characteristics of peripheral blood stem cells mobilised with cyclophosphamide and the delayed addition of G-CSF. Bone Marrow Transplant (1995) 0.77
Interaction of aluminium and gallium with human lymphocytes: the role of transferrin. Biochim Biophys Acta (1991) 0.77
Allogeneic bone marrow transplant for multiple myeloma. Blood (1997) 0.76
Autologous GVHD following PBSCT, with evidence for a graft-versus-myeloma effect. Bone Marrow Transplant (1997) 0.76
High serum vitamin B12 binding capacity as a marker of the fibrolamellar variant of hepatocellular carcinoma. Br Med J (Clin Res Ed) (1983) 0.76
Peripheral blood stem cells for allogeneic transplantation. Bone Marrow Transplant (1994) 0.76
Camptothecin-induced apoptosis in non-small cell lung cancer is independent of cyclooxygenase expression. Apoptosis (2003) 0.76
IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosphamide, carboplatin and etoposide) in the context of salvage therapy for lymphoma. Br J Haematol (2008) 0.76
Thrombocytopathy associated with autoimmune haemolytic anaemia. Br Med J (1978) 0.76
Interleukin-1 is one factor which regulates autocrine production of GM-CSF by the blast cells of acute myeloblastic leukaemia. Br J Haematol (1990) 0.76
Platelet adenine nucleotides and arachidonic acid metabolism in the myeloproliferative disorders. Thromb Res (1981) 0.76
Second allogeneic transplant for severe aplastic anaemia following late graft rejection. Br J Haematol (1999) 0.75
Sensitivity of S. cerevisiae in haematology patients. J Hosp Infect (2001) 0.75
Anticorresponding p15 promoter methylation and microsatellite instability in acute myeloblastic leukemia. Blood (2000) 0.75
High-dose chemotherapy and autologous peripheral blood stem cell transplantation in lymphoma without blood product support. Bone Marrow Transplant (2000) 0.75